Inactive Instrument

Press Releases Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Pardes Biosciences Announces Closing of Tender Offer	23-08-31	AQ
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences	23-08-28	BU
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares	23-08-17	BU
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	23-08-07	BU
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	23-07-21	BU
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm	23-07-19	BU
PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders	23-07-17	BU
Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific	23-07-17	PR
Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights	23-07-17	AQ
PARDES BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	23-05-18	AQ
PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-05	AQ
PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)	23-05-05	AQ
Pardes Biosciences Reports First Quarter 2023 Financial Results	23-05-05	AQ
PARDES BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-21	AQ
PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	23-04-03	AQ
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19	23-04-03	AQ
PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-14	AQ
PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)	23-03-14	AQ
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update	23-03-14	AQ
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference	23-02-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Press Releases

Filters